Document is current

Article History

Received: 7 August 2017

Accepted: 25 April 2018

First Online: 22 May 2018

Authors’ information

: AT: Is a Consultant Lung Transplant Physician in Nantes, France. MFT: Is a Consultant Paediatric Respiratory Physician in Newcastle upon Tyne, United Kingdom. PAC: Is Professor of Thoracic Medicine at Newcastle University and Consultant Lung Transplant Physician at the Freeman Hospital, United Kingdom; he is past-president of the International Society for Heart and Lung Transplantation (ISHLT) and was invited to debate the issue of lung transplantation in people with CF and infection with M. abscessus at the 2017 Annual Meeting of the ISHLT, San Diego, April 2017. MB: Is a MRC Clinician Scientist/Clinical Senior Lecturer at Newcastle University and Honorary Consultant in Paediatric Respiratory Medicine in Newcastle upon Tyne, United Kingdom.

: Annonymised survey to clinicians at transplant centres, ethical approval therefore not required as per Health Research Agency, London, United Kingdom (ExternalRef removed).

: AT: None. MFT: Not related to this work: investigator-led research grant from Pfizer. PAC: Not related to this work: investigator-led research grants from Bayer, Actelion and GSK; advisory boards for Bayer and Actelion. MB: Not related to this work: investigator-led research grants from Pfizer and Roche Diagnostics; speaker fees for educational events paid to Newcastle University from Novartis, Roche Diagnostics and Teva.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.